论文部分内容阅读
肾细胞癌(renal cell carcinoma,RCC)作为泌尿系统常见的恶性肿瘤,约占所有恶性肿瘤的2%~3%,过去20年间发病率在世界范围内增高约2%,以发达国家更为多发,评估探讨RCC生物学特性,同时制定实施最合宜的治疗方案,对于RCC诊治及转归尤为重要。随着影像诊断学及外科技术等领域的综合性进展,因偶然体检早期确诊T_1 期RCC患者日益增多,而有关其诊疗及预后等也逐渐得到实质性的改善和提高。尽管如此,研究显示仍有少数T_1 期RCC患者在确诊后发现淋巴结转移或远处转移。本文就T_1N_1M_0期肾癌的相关治疗进展做一综述。
Renal cell carcinoma (RCC) is a common malignant tumor in the urinary system accounting for about 2% to 3% of all malignant tumors. The incidence of RCC in the world over the past 20 years is about 2% higher than that in developed countries, Evaluation of the biological characteristics of RCC, and to develop the most appropriate treatment plan for RCC diagnosis and treatment is particularly important. With the comprehensive progress in the fields of imaging diagnosis and surgical technique, the number of RCC patients diagnosed early by T - 1 in occasional physical examination is increasing day by day, and their diagnosis, treatment and prognosis have also been gradually improved and improved. However, studies show that there are still a few patients with T_1 RCC who have been diagnosed with lymph node metastasis or distant metastasis. This article reviews the progress of T_1N_1M_0 renal cell carcinoma.